Investors Presentation - Q1FY27

AI summary - Q1FY27 revenue 139.16 Cr +33.6% y-y; EBITDA 23.29 Cr +112.2% y-y; EBITDA margin 16.7% +620 bps y-y; PAT 18.40 Cr +99.1% y-y - Management: sustained demand momentum; margins boosted by inventory gains and forex mark-to-market reversal - Capex Phase II on schedule; commissioning expected Q2FY27; supports growth and new market opportunities - Segment mix stable with 95% Animal API; geographic mix led by Asia and ROW - Strategy: brownfield and greenfield expansions underway; ₹210 Cr capex planned funded by debt and accruals - Market leadership in veterinary APIs with 45 products and strong global presence - Manufacturing: 5 state-of-the-art facilities with WHO-GMP and ISO accreditations - Customer concentration improving; top 5 customers now 26% of sales - Medium-term outlook confident on demand and operating leverage